tldrdaily.news logo
Tag

Lorbrena

All articles tagged with #lorbrena

businesshealth1 year ago

Pfizer's Lung Cancer Drug Projected to Surpass $1 Billion in Sales

Pfizer anticipates its lung cancer drug Lorbrena will surpass $1 billion in annual sales by 2030, driven by strong five-year clinical trial data showing significant disease progression-free survival rates in patients with ALK-positive advanced lung cancer. The drug, which outperforms Pfizer's earlier treatment Xalkori, has shown particularly promising results in patients with brain metastases and is expected to see substantial market growth, especially in China.

via Fox Business|
#alk-mutation#businesshealth#lorbrena
health1 year ago

Pfizer's Lung Cancer Drug Shows Record-Breaking Results and Billion-Dollar Potential

Pfizer's drug Lorbrena has shown promising long-term results in a late-stage trial for advanced non-small cell lung cancer with the ALK mutation, potentially establishing it as the new standard treatment. The drug significantly extended progression-free survival and reduced brain metastases compared to Pfizer's older drug Xalkori. The findings will be presented at the American Society of Clinical Oncology annual meeting.

via CNBC|
#alk-inhibitors#clinical-trials#health
health1 year ago

Pfizer's Lorbrena Shows 81% Reduction in Rare Lung Cancer Progression

Pfizer's Lorbrena, a treatment for non-small cell lung cancer with specific genetic mutations, has shown an 81% reduction in cancer progression or death over five years in updated clinical trial data, significantly outperforming another Pfizer drug, Xalkori. Despite its impressive efficacy, Lorbrena's sales constitute only a small fraction of Pfizer's annual revenue.

via STAT|
#clinical-trial#fda-approval#health
health1 year ago

Pfizer's Lorbrena Shows Breakthrough Results in Advanced Lung Cancer Trials

Pfizer's drug Lorbrena significantly extends the life expectancy of patients with ALK-positive non-small cell lung cancer, a rare and particularly deadly form of the disease. New research shows that 60% of patients treated with Lorbrena were still alive after five years, compared to 8% of those treated with crizotinib. Lorbrena also effectively prevents brain metastasis, a common and severe complication of ALK-positive lung cancer. However, the drug may cause more neurotoxic side effects, which can be managed by adjusting the dosage.

via NBC News|
#alk-mutation#clinical-trial#health